Table 3.
Prospective studies of consolidative high dose chemotherapy and autologous stem cell transplant in the primary treatment of PTCL
Survival estimates are rounded off.
*ORR after the chemotherapy phase.
†Includes CRu.
‡Combined results of 2 phase 2 studies.
§High-dose sequential was APO × 2 (doxorubicin, vincristine, prednisone) and DHAP × 2, MACOPB × 8 weeks, then a 3-day course of MAD (mitoxantrone, AraC, dexamethasone).
